AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31751936 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release sodium bicarbonate (DEL)
Number of subjects: 14
Study 31751936 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate (all forms)
Number of subjects: 14
Study 30480353 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity endurance training (END; n = 10)
Number of subjects: 21
Study 30480353 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume high-intensity interval training (HIIT; n = 11)
Number of subjects: 21
Study 27987228 — intervention group
Group type: EXPERIMENTAL
Intervention: Xen2174 2.5 mg
Number of subjects: 25
Study 27987228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 25204316 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.9 g of eicosapentaenoic acid plus docosahexaenoic acid for 12 weeks
Number of subjects: 38
Study 25204316 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 38
Study 23158805 — intervention group
Group type: EXPERIMENTAL
Intervention: Intent to use long-acting reversible contraception (LARC)
Number of subjects: 800
Study 23158805 — intervention group
Group type: EXPERIMENTAL
Intervention: Not trying for pregnancy at time of conception
Number of subjects: 800
Study 23158805 — intervention group
Group type: EXPERIMENTAL
Intervention: No desire for another pregnancy within 2 years
Number of subjects: 800
Study 21455709 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (125 mg)
Number of subjects: 36
Study 21455709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 19081225 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-focused attention and safety behaviors experiment
Number of subjects: 0
Study 19081225 — intervention group
Group type: EXPERIMENTAL
Intervention: Video feedback experiment
Number of subjects: 0
Study 17355022 — intervention group
Group type: EXPERIMENTAL
Intervention: Marmot operation
Number of subjects: 70
Study 17355022 — intervention group
Group type: COMPARATOR
Intervention: Conventional laminectomy
Number of subjects: 70
Study 14760802 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind subacromial injection of 20 mg triamcinolone (Group 1, n = 20)
Number of subjects: 41
Study 14760802 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographic guided injection of 20 mg triamcinolone (Group 2, n = 21)
Number of subjects: 41
Study 14760802 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 41
Study 11433902 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 51
Study 11433902 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 51
Study 9503046 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 microgram calcitriol plus 500 mg calcium daily for 6 months
Number of subjects: 26
Study 9503046 — intervention group
Group type: COMPARATOR
Intervention: 800 IU cholecalciferol and 1000 mg calcium daily for 6 months
Number of subjects: 26
Study 9503046 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (calcitriol and cholecalciferol)
Number of subjects: 26
Study 7995063 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.02% mitomycin C for 5 min at the completion of surgery
Number of subjects: 40
Study 7995063 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% instead of mitomycin C
Number of subjects: 40
Study 31686586 — intervention group
Group type: EXPERIMENTAL
Intervention: ORIF with arthroscopic debridement
Number of subjects: 50
Study 31686586 — intervention group
Group type: COMPARATOR
Intervention: ORIF without arthroscopic debridement
Number of subjects: 50
Study 29593017 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) plus on-demand gastrocaine
Number of subjects: 132
Study 29593017 — intervention group
Group type: COMPARATOR
Intervention: Waiting list to EA plus on-demand gastrocaine
Number of subjects: 132
Study 25953327 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (375 mg/day)
Number of subjects: 40
Study 25953327 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (blood level 200-300 ng/ml)
Number of subjects: 40
Study 25953327 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study 24445180 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk Avoidance (RA) program
Number of subjects: 1187
Study 24445180 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk Reduction (RR) program
Number of subjects: 1187
Study 24445180 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1187
Study 22470921 — intervention group
Group type: EXPERIMENTAL
Intervention: Vatreptacog alfa (5, 10, 20, 40, and 80 µg kg(‐1))
Number of subjects: 51
Study 22470921 — intervention group
Group type: COMPARATOR
Intervention: Recombinant FVIIa (rFVIIa) at 90 µg kg(‐1)
Number of subjects: 51
Study 20166794 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 10 mg/day
Number of subjects: 302
Study 20166794 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 30 mg/day
Number of subjects: 302
Study 20166794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 18083724 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist osteoporosis nurses training care home staff
Number of subjects: 5637
Study 18083724 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 5637
Study 16497602 — intervention group
Group type: EXPERIMENTAL
Intervention: Guía+ITEMs (individually timed educational messages)
Number of subjects: 4000
Study 16497602 — intervention group
Group type: COMPARATOR
Intervention: Guía+ITEMs+a mood management course
Number of subjects: 4000
Study 16497602 — intervention group
Group type: COMPARATOR
Intervention: Guía (standard smoking cessation guide)
Number of subjects: 4000
Study 16497602 — intervention group
Group type: EXPERIMENTAL
Intervention: Guía+ITEMs
Number of subjects: 4000
Study 16497602 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with past MDEs
Number of subjects: 4000
Study 16497602 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with current MDEs
Number of subjects: 4000
Study 12930193 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation Training (CT, n = 7)
Number of subjects: 15
Study 12930193 — intervention group
Group type: COMPARATOR
Intervention: Maintenance Training (MT, n = 8)
Number of subjects: 15
Study 10716460 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose heparin (300 IU/kg)
Number of subjects: 584
Study 10716460 — intervention group
Group type: COMPARATOR
Intervention: Low dose heparin (0 or 5,000 IU)
Number of subjects: 584
Study 9184580 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (2 mg/min)
Number of subjects: 30
Study 9184580 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 30
Study 8263864 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative fluid instillation (1-2 L)
Number of subjects: 137
Study 8263864 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fluid instillation)
Number of subjects: 137
Study 2993733 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bran (35 g)
Number of subjects: 7
Study 31605203 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Hz stimulation
Number of subjects: 19
Study 31605203 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 Hz stimulation
Number of subjects: 19
Study 29508539 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-delivered cognitive behavioural therapy
Number of subjects: 52
Study 29508539 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based cognitive behavioural therapy
Number of subjects: 52
Study 29508539 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 52
Study 27170728 — intervention group
Group type: EXPERIMENTAL
Intervention: OJ with 5.5 g added orange pomace fiber (OPF)
Number of subjects: 36
Study 27170728 — intervention group
Group type: COMPARATOR
Intervention: Control (isocaloric sugar-matched)
Number of subjects: 36
Study 24950270 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineal low rectal dissection
Number of subjects: 100
Study 24950270 — intervention group
Group type: COMPARATOR
Intervention: Abdominal low rectal dissection
Number of subjects: 100
Study 22589080 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological intervention delivered by family members
Number of subjects: 287
Study 22589080 — intervention group
Group type: COMPARATOR
Intervention: Standard management
Number of subjects: 287
Study 19829124 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopromide (low-osmolar) contrast media
Number of subjects: 0
Study 19829124 — intervention group
Group type: COMPARATOR
Intervention: Iodixanol (iso-osmolar) contrast media
Number of subjects: 0
Study 19829124 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose N-acetylcysteine (1200 mg intravenously during the procedure and 1200 mg orally two times daily for the next 48 h after percutaneous coronary intervention)
Number of subjects: 0
Study 17276271 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrasound mode (US)
Number of subjects: 525
Study 17276271 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsional mode
Number of subjects: 525
Study 16137113 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg docosahexaenoic acid (DHA)
Number of subjects: 0
Study 16137113 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg 5‐methyl‐tetra‐hydro‐folate (5‐MTHF)
Number of subjects: 0
Study 16137113 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 500 mg DHA and 400 mg 5‐MTHF
Number of subjects: 0
Study 16137113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11875284 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant treatment
Number of subjects: 206
Study 11875284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 10449958 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% all‐trans‐retinoic acid (RA)
Number of subjects: 0
Study 10449958 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% 2‐hydroxy‐5‐octanoyl benzoic acid (beta‐lipohydroxy acid, LSA)
Number of subjects: 0
Study 10449958 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% glycolic acid (GA)
Number of subjects: 0
Study 10449958 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 0
Study 7598525 — intervention group
Group type: COMPARATOR
Intervention: iC3b-coated erythrocytes
Number of subjects: 18
Study 7598525 — intervention group
Group type: COMPARATOR
Intervention: IgG-coated erythrocytes
Number of subjects: 18
Study 2151757 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (GR38032F)
Number of subjects: 10
Study 2151757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 373852 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol given by intermittent positive-pressure breathing (IPPB) for three minutes
Number of subjects: 19
Study 373852 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol given intravenously (500 microgram injection)
Number of subjects: 19
Study 373852 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol given by intermittent positive-pressure breathing (IPPB)
Number of subjects: 19
Study 373852 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (IPPB and intravenous)
Number of subjects: 19
Study 31684705 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Recovery (AR)
Number of subjects: 45
Study 31684705 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation (NMES)
Number of subjects: 45
Study 31684705 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam Rolling (FR)
Number of subjects: 45
Study 30112581 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural mobilization (NM) exercises targeting the median, musculocutaneous, femoral, and saphenous nerve, performed twice daily for 4-8 weeks.
Number of subjects: 21
Study 30112581 — intervention group
Group type: COMPARATOR
Intervention: Gentle joint mobilization exercises targeting the same joints (Control group).
Number of subjects: 21
Study 30112581 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural mobilization (NM) exercises (same as above).
Number of subjects: 21
Study 27506836 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625mg/d conjugated equine estrogens (CEE) for those with prior hysterectomy (mean 7.1 years)
Number of subjects: 4156
Study 27506836 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE with 2.5mg/d medroxyprogesterone acetate for those without prior hysterectomy (mean 5.4 years)
Number of subjects: 4156
Study 27506836 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy in women aged 65-79 years
Number of subjects: 4156
Study 27506836 — intervention group
Group type: COMPARATOR
Intervention: Matching placebos
Number of subjects: 4156
Study 25888828 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care intervention (test groups)
Number of subjects: 162
Study 25888828 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care intervention (test 1 group)
Number of subjects: 162
Study 25888828 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care intervention (test 2 group)
Number of subjects: 162
Study 25888828 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 162
Study 24004621 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingival scaling/root planning (SRP)
Number of subjects: 18
Study 24004621 — intervention group
Group type: COMPARATOR
Intervention: Occlusal adjustment
Number of subjects: 18
Study 24004621 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of SRP and occlusal adjustment
Number of subjects: 18
Study 21389041 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum retinol concentrations at baseline (quintile 5)
Number of subjects: 29004
Study 21389041 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintile of serum retinol at both baseline and 3 years (quintile 5/quintile 5)
Number of subjects: 29004
Study 19178509 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP infusion at a rate of 2 pmol/kg/min for 4 h
Number of subjects: 12
Study 19178509 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion for 4 h
Number of subjects: 12
Study 19178509 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP‐1 infusion at a rate of 1 pmol/kg/min for 4 h
Number of subjects: 12
Study 19178509 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP‐1 (at 1 pmol/kg/min) with GIP (at 2 pmol/kg/min)
Number of subjects: 12
Study 19178509 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum energy intake after all four infusions
Number of subjects: 12
Study 17102935 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified, but involves three treatments for borderline personality disorder (BPD).
Number of subjects: 0
Study 17102935 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessors diagnosing BPD and comorbid diagnoses.
Number of subjects: 0
Study 15103752 — intervention group
Group type: COMPARATOR
Intervention: T-tube
Number of subjects: 260
Study 15103752 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV) 8 cm H2O
Number of subjects: 260
Study 11032702 — intervention group
Group type: COMPARATOR
Intervention: NN703 (tabimorelin) 3.0 mg/kg
Number of subjects: 0
Study 11032702 — intervention group
Group type: COMPARATOR
Intervention: NN703 (tabimorelin) 6.0 mg/kg
Number of subjects: 0
Study 11032702 — intervention group
Group type: COMPARATOR
Intervention: NN703 (tabimorelin) 12.0 mg/kg
Number of subjects: 0
Study 11032702 — intervention group
Group type: COMPARATOR
Intervention: NN703 (tabimorelin) 1.5 mg/kg
Number of subjects: 0
Study 9306740 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable Fatigue Meter (PFM)
Number of subjects: 2
Study 9306740 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance between the PFM and the eyes
Number of subjects: 2
Study 9306740 — intervention group
Group type: COMPARATOR
Intervention: Room illumination
Number of subjects: 2
Study 8339398 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (low doses, transdermal patch)
Number of subjects: 36
Study 8339398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 3555041 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (750 mg orally every 12 hours)
Number of subjects: 56
Study 3555041 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (2.0 g intravenously every 8 hours)
Number of subjects: 56
Study 3555041 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin and Cefotaxime combined cure rate
Number of subjects: 56
Study 31451986 — intervention group
Group type: EXPERIMENTAL
Intervention: AutonoMe automated delivery system
Number of subjects: 40
Study 31451986 — intervention group
Group type: COMPARATOR
Intervention: Monarch III injector system
Number of subjects: 40
Study 31513531 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold compress
Number of subjects: 50
Study 31513531 — intervention group
Group type: EXPERIMENTAL
Intervention: Xyla-P cream
Number of subjects: 50
Study 31513531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 28086137 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 150
Study 28086137 — intervention group
Group type: COMPARATOR
Intervention: Tolperisone
Number of subjects: 150
Study 25569408 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ketamine (0.5 mg/kg)
Number of subjects: 120
Study 25569408 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal ketamine (0.5 mg/kg)
Number of subjects: 120
Study 25569408 — intervention group
Group type: EXPERIMENTAL
Intervention: Local peritonsillar ketamine (2 mg/kg)
Number of subjects: 120
Study 25569408 — intervention group
Group type: COMPARATOR
Intervention: IV tramadol hydrochloride (2 mg/kg)
Number of subjects: 120
Study 23521578 — intervention group
Group type: EXPERIMENTAL
Intervention: Color change
Number of subjects: 28
Study 23521578 — intervention group
Group type: COMPARATOR
Intervention: Rotational motion change
Number of subjects: 28
Study 22321929 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hypervolemic hemodilution (AHH) with 6% hydroxyethyl starch solution at 24 ml×kg(‐1)×h(‐1)
Number of subjects: 80
Study 22321929 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving compound electrolyte solution at 6 ml×kg(‐1)×h(‐1)
Number of subjects: 80
Study 22321929 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hypervolemic hemodilution (AHH)
Number of subjects: 80
Study 18339727 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational Therapy (OT) - six home treatment sessions over 2 months
Number of subjects: 39
Study 16782687 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitized speech output
Number of subjects: 90
Study 16782687 — intervention group
Group type: EXPERIMENTAL
Intervention: DECTalk synthesized speech output
Number of subjects: 90
Study 16782687 — intervention group
Group type: EXPERIMENTAL
Intervention: MacinTalk synthesized speech output
Number of subjects: 90
Study 16782687 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextual information (topic cue)
Number of subjects: 90
Study 16782687 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer messages (sentences)
Number of subjects: 90
Study 16782687 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentences
Number of subjects: 90
Study 15305234 — intervention group
Group type: EXPERIMENTAL
Intervention: DRB1*04 allele
Number of subjects: 91
Study 15305234 — intervention group
Group type: EXPERIMENTAL
Intervention: DQB1*03 allele
Number of subjects: 91
Study 15305234 — intervention group
Group type: COMPARATOR
Intervention: Goitrous form
Number of subjects: 91
Study 11977294 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-insulin-kalium (GIK) mixture
Number of subjects: 0
Study 11977294 — intervention group
Group type: COMPARATOR
Intervention: Placebo (physiological saline infusion)
Number of subjects: 0
Study 9042978 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily after initial 1-week triple therapy
Number of subjects: 59
Study 9042978 — intervention group
Group type: COMPARATOR
Intervention: Placebo after initial 1-week triple therapy
Number of subjects: 59
Study 9042978 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week low-dose triple therapy (omeprazole 20 mg b.d., clarithromycin 250 mg b.d., metronidazole 400 mg b.d.)
Number of subjects: 59
Study 9042978 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week low-dose triple therapy
Number of subjects: 59
Study 7934983 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic VLCD (615-kcal/d) for 28 days
Number of subjects: 16
Study 7934983 — intervention group
Group type: COMPARATOR
Intervention: Nonketogenic VLCD (615-kcal/d) for 28 days
Number of subjects: 16
Study 2829958 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of fish oil daily containing approximately 1.8 g eicosapentaenoic acid
Number of subjects: 0
Study 2829958 — intervention group
Group type: COMPARATOR
Intervention: Isoenergetic amount of olive oil
Number of subjects: 0
Study 31613144 — intervention group
Group type: EXPERIMENTAL
Intervention: Frankel 2 appliance (FR2)
Number of subjects: 60
Study 31613144 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Twin Block appliance (MTB)
Number of subjects: 60
Study 31613144 — intervention group
Group type: COMPARATOR
Intervention: Control group (not applicable)
Number of subjects: 60
Study 29560570 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly injections
Number of subjects: 277
Study 29560570 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly vaginal ring
Number of subjects: 277
Study 29560570 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral tablets
Number of subjects: 277
Study 29137681 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet group
Number of subjects: 150
Study 29137681 — intervention group
Group type: COMPARATOR
Intervention: Non-tourniquet group
Number of subjects: 150
Study 26605710 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week lifestyle intervention
Number of subjects: 69
Study 26605710 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 69
Study 23557730 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 text messages about skin cancer prevention, skin self-examination, or physical activity (attention control) over one year
Number of subjects: 678